Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Mark Lovell to Aged, 80 and over

This is a "connection" page, showing publications Mark Lovell has written about Aged, 80 and over.

 
Connection Strength
  
 
 
1.102
  
  1. Ellison EM, Bradley-Whitman MA, Lovell MA. Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects. J Mol Neurosci. 2017 Oct; 63(2):185-197.
    View in: PubMed
    Score: 0.067
  2. Ellison EM, Abner EL, Lovell MA. Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease. J Neurochem. 2017 02; 140(3):383-394.
    View in: PubMed
    Score: 0.064
  3. Bradley-Whitman MA, Abner E, Lynn BC, Lovell MA. A Novel Plasma Based Biomarker of Alzheimer's Disease. J Alzheimers Dis. 2015; 47(3):761-71.
    View in: PubMed
    Score: 0.056
  4. Bradley-Whitman MA, Timmons MD, Beckett TL, Murphy MP, Lynn BC, Lovell MA. Nucleic acid oxidation: an early feature of Alzheimer's disease. J Neurochem. 2014 Jan; 128(2):294-304.
    View in: PubMed
    Score: 0.051
  5. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of Alzheimer's disease. Mech Ageing Dev. 2013 Oct; 134(10):486-95.
    View in: PubMed
    Score: 0.051
  6. Lovell MA, Bradley MA, Fister SX. 4-Hydroxyhexenal (HHE) impairs glutamate transport in astrocyte cultures. J Alzheimers Dis. 2012; 32(1):139-46.
    View in: PubMed
    Score: 0.045
  7. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging. 2012 Jun; 33(6):1034-44.
    View in: PubMed
    Score: 0.042
  8. Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med. 2010 Jun 15; 48(12):1570-6.
    View in: PubMed
    Score: 0.040
  9. Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. J Alzheimers Dis. 2010; 19(1):325-39.
    View in: PubMed
    Score: 0.039
  10. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 2010 Mar; 20(2):343-50.
    View in: PubMed
    Score: 0.037
  11. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology. 2008 Jun 03; 70(23):2212-8.
    View in: PubMed
    Score: 0.035
  12. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007; 35(22):7497-504.
    View in: PubMed
    Score: 0.034
  13. Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis. 2008 Feb; 29(2):169-75.
    View in: PubMed
    Score: 0.033
  14. Lovell MA, Smith JL, Markesbery WR. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. J Neuropathol Exp Neurol. 2006 May; 65(5):489-98.
    View in: PubMed
    Score: 0.031
  15. Smith JL, Xiong S, Markesbery WR, Lovell MA. Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience. 2006 Jul 07; 140(3):879-88.
    View in: PubMed
    Score: 0.030
  16. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem. 2006 Feb; 96(3):825-32.
    View in: PubMed
    Score: 0.030
  17. Lovell MA, Markesbery WR. Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease. J Neuropathol Exp Neurol. 2005 Aug; 64(8):675-80.
    View in: PubMed
    Score: 0.029
  18. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging. 2006 Aug; 27(8):1094-9.
    View in: PubMed
    Score: 0.029
  19. Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol Aging. 2006 Jul; 27(7):909-17.
    View in: PubMed
    Score: 0.029
  20. Lovell MA, Smith JL, Xiong S, Markesbery WR. Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. Neurotox Res. 2005; 7(4):265-71.
    View in: PubMed
    Score: 0.028
  21. Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res. 2003 Sep 05; 983(1-2):84-96.
    View in: PubMed
    Score: 0.025
  22. Lovell MA, Robertson JD, Buchholz BA, Xie C, Markesbery WR. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging. 2002 Mar-Apr; 23(2):179-86.
    View in: PubMed
    Score: 0.023
  23. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging. 2001 Mar-Apr; 22(2):187-94.
    View in: PubMed
    Score: 0.021
  24. Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol. 2001 Mar; 58(3):392-6.
    View in: PubMed
    Score: 0.021
  25. Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 2000 Feb 07; 855(1):116-23.
    View in: PubMed
    Score: 0.020
  26. Lovell MA, Xie C, Gabbita SP, Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med. 2000 Feb 01; 28(3):418-27.
    View in: PubMed
    Score: 0.020
  27. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem. 1999 Feb; 72(2):771-6.
    View in: PubMed
    Score: 0.018
  28. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 1998 Dec; 51(6):1562-6.
    View in: PubMed
    Score: 0.018
  29. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998 Jan-Feb; 19(1):33-6.
    View in: PubMed
    Score: 0.017
  30. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging. 1997 Sep-Oct; 18(5):457-61.
    View in: PubMed
    Score: 0.017
  31. Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N, Martin J, Lam L, Aggarwal R, McCaffrey N, Currow D, Chye R, Lovell M, McGregor I, Agar M. Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Intern Med J. 2016 Nov; 46(11):1269-1275.
    View in: PubMed
    Score: 0.016
  32. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995 Aug; 45(8):1594-601.
    View in: PubMed
    Score: 0.014
  33. Lovell MA, Ehmann WD, Markesbery WR. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann Neurol. 1993 Jan; 33(1):36-42.
    View in: PubMed
    Score: 0.012
  34. Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, Cooper G, Mendiondo M, Danner DD, Van Eldik LJ, Caban-Holt A, Lovell MA, Kryscio RJ. University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res. 2012 Jul; 9(6):724-33.
    View in: PubMed
    Score: 0.012
  35. Weidner AM, Bradley MA, Beckett TL, Niedowicz DM, Dowling AL, Matveev SV, LeVine H, Lovell MA, Murphy MP. RNA oxidation adducts 8-OHG and 8-OHA change with A?42 levels in late-stage Alzheimer's disease. PLoS One. 2011; 6(9):e24930.
    View in: PubMed
    Score: 0.011
  36. Liu X, Lovell MA, Lynn BC. Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. Chem Res Toxicol. 2006 May; 19(5):710-8.
    View in: PubMed
    Score: 0.008
  37. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005 Nov; 58(5):730-5.
    View in: PubMed
    Score: 0.007
  38. Wenner BR, Lovell MA, Lynn BC. Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res. 2004 Jan-Feb; 3(1):97-103.
    View in: PubMed
    Score: 0.006
  39. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem. 1999 Oct; 73(4):1660-6.
    View in: PubMed
    Score: 0.005
  40. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem. 1998 Nov; 71(5):2034-40.
    View in: PubMed
    Score: 0.005
  41. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 1998 Jan; 23(1):81-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)